Her4 human receptor tyrosine kinase
CA 2103323 A1 · Owner: Bristol-Myers Squibb Company · Inventors: Shoyab, Mohammed; Culouscou, Jean-Michel; Plowman, Gregory D.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The molecular cloning, expression and biological, characteristics of a novel receptor tyrosine kinase related to the epidermal growth factor receptor termed HER4/p180erbB4, are described. A HER4 ligand capable of inducing cellular differentiation of breast cancer cells is also disclosed. In view of the expression of HER4 in several human cancers and in certain tissues of neuronal and muscular origin various diagnostic and therapeutic uses of HER4-derived and HER4-related biological compositions are provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 17, 1993. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 17, 2013.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 17, 2015.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.